Projects per year
Personal profile
Biography
Shaun is a clinical and laboratory haematologist who works in both patient facing and clinical research in haematology. He completed haematology training at Peter MacCallum Cancer Centre, The Royal Melbourne Hospital, Melbourne Pathology and St Vincent's Hospital Melbourne before completing a fellowship in Acute Leukaemia at the Alfred Hospital. He works as the head of the myeloid diseases service at Alfred Health with a focus on management of acute leukaemia, clinical trials and clinical research in Acute Leukaemia. Shaun has led national studies in Acute Lymphoblastic Leukaemia (ALL) focusing on delivery of novel therapies in older adults with ALL.
Research interests
Shaun's research interests are in Acute Leukaemia with a focus on clinical research into the application of novel therapies in Acute Leukaemia, measurable residual disease (MRD) and application of novel prognostic scoring systems through the use of machine learning and artificial intelligence. He is a principal investigator on many studies focused on novel therapeutics in both Acute Myeloid Leukaemia and Acute Lymphoblastic Leukaemia and leads a team that includes clinical trials in Myelodysplasia and other myeloid disorders.
Supervision interests
Interested in supervision of clinical PhD students with a focus on clinical or translational research in Acute Leukaemia.
Monash teaching commitment
Lecturer to MBBS course.
Clinical activities
Head of myeloid diseases service - Alfred Health.
Consulting
Consulting to Amgen, Abbvie, BMS, Gilead/Kite, Novartis and Pfizer
University Service
PhD student supervisor.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
PhD
… → 2023
External positions
Haematologist - Epworth Healthcare
Research area keywords
- Haematology
- Leukaemia
- Minimal Residual Disease
- Acute lymphoblastic leukaemia
- Acute Myeloid Leukaemia
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial of Quizartinib Administered in Combination with Induction and Consolidation Chemotherapy and Administered as Maintenance Therapy in Adult Patients with Newly Diagnosed FLT3-ITD Negative Acute Myeloid Leukemia (QuANTUM-Wild)
Fleming, S. (Primary Chief Investigator (PCI))
21/08/25 → 20/08/27
Project: Research
-
A Phase 1, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of SNDX-5613 in Combination with Intensive Chemotherapy in Participants with Newly Diagnosed Acute Myeloid Leukemias Harboring Alterations in Lysine-specific Methyltransferase 2A (KMT2A/MLL), Nucleophosmin 1 (NPM1), and Nucleoporin 98 (NUP98) Genes
Fleming, S. (Primary Chief Investigator (PCI))
9/05/25 → 8/05/27
Project: Research
-
The ACRF Centre for Dynamic Immuno-Oncology (CDIO)
Shackleton, M. (Primary Chief Investigator (PCI)), Cherk, M. (Chief Investigator (CI)), Naranbhai, V. (Chief Investigator (CI)), McLean, C. (Chief Investigator (CI)), Monif, M. (Chief Investigator (CI)), Si Lun Tam, C. (Chief Investigator (CI)), Kalff, A. (Chief Investigator (CI)), Fleming, S. (Chief Investigator (CI)), Mar, V. (Chief Investigator (CI)), Ge, Z. (Chief Investigator (CI)) & Cheung, J. (Project Manager)
7/04/25 → 7/01/30
Project: Research
-
A Phase 1 open-label trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary antitumor activity of LAVA-1266, a CD123-targeting bispecific Vγ9Vδ2-T cell engager, in patients with CD123 positive relapsed/refractory acute myeloid leukemia and intermediate risk, high risk, or extremely high risk myelodysplastic syndrome
Fleming, S. (Primary Chief Investigator (PCI))
31/10/24 → 30/10/26
Project: Research
-
A Phase 1, Open-label, Dose Escalation and Dose Expansion, Multicenter Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ZE46-0134 in Adults with FLT3 mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)
Fleming, S. (Primary Chief Investigator (PCI))
28/08/24 → 28/08/26
Project: Research
-
ALLG APML5: bioavailability and safety of oral arsenic trioxide assessed during consolidation therapy for APL
Iland, H. J., Reynolds, J., Boddy, A. V., Schultz, H. B., Khoo, L., Fleming, S., Lane, S. W., Weber, N., Gasiorowski, R., Armytage, T., Harrup, R., Watson, A. M., Tan, P., Filshie, R., Kwok, F., Stevenson, W., Yuen, S., Ng, A. P., Rowley, L. & Marlton, P. & 2 others, , 25 Mar 2025, In: Blood Advances. 9, 6, p. 1476-1484 9 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access3 Citations (Scopus) -
CLOX and neurotox: Utility of the clock drawing task in monitoring for immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor T-cell therapy
Kazzi, C., Simpson, T., Wronski, M., Seery, N., Wesselingh, R., Tan, T. H., Ko, K. Y., Pearce, D. J., Abbott, C., Li, J., Griffith, S. P., Wong, S. M., Westworth, M., Inam, S., Tam, C. S., Fleming, S., Van Der Walt, A., O'Brien, T. J., Alpitsis, R. & Spencer, A. & 3 others, , Oct 2025, In: British Journal of Haematology. 207, 4, p. 1495-1503 9 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access -
Final analysis of the phase 1b Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT)
Chua, C. C., Loo, S., Fong, C. Y., Ting, S. B., Tiong, I. S., Fleming, S., Anstee, N. S., Ivey, A., Ashby, M., Teh, T. C., Reynolds, J., Roberts, A. W. & Wei, A. H., 22 Apr 2025, In: Blood Advances. 9, 8, p. 1827-1835 9 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access6 Citations (Scopus) -
Monitoring the neurological complications of chimeric antigen receptor (CAR) T-cell therapy in patients with sensory and physical impairments and non-native-speaking backgrounds using modified immune effector cell-associated encephalopathy (ICE) scores: a case series
Kazzi, C., Simpson, T., Abbott, C., Wronski, M., Seery, N., Tan, T. H. L., Wesselingh, R., Ko, K., Wong, S. M., Inam, S., Tam, C., Fleming, S., O’Brien, T. J., Alpitsis, R., Spencer, A., Malpas, C. & Monif, M., 12 Feb 2025, In: BMJ Neurology Open. 7, 1, 9 p., e000927.Research output: Contribution to journal › Article › Research › peer-review
Open Access -
Neurotoxicity associated with chimeric antigen receptor T-cell therapy
Wronski, M., Wesselingh, R., Kazzi, C., Seery, N., Ko, K., Li, J., Tan, T. H., Simpson, T., Abbott, C., Fleming, S., Inam, S., Tam, C. S., Wong, S. M., O'Brien, T., van der Walt, A., Spencer, A., Butzkueven, H. & Monif, M., 15 Oct 2025, In: Journal of Neuroimmunology. 407, 25 p., 578717.Research output: Contribution to journal › Article › Research › peer-review
Open Access